公开(公告)号：US10308704B2

公开(公告)日：2019-06-04

申请号：US15004375

申请日：2016-01-22

Applicant: Amgen Inc.

Inventor： Jeonghoon Sun ,  Lei-Ting Tony Tam ,  Mark Leo Michaels ,  Thomas Charles Boone ,  Rohini Deshpande ,  Yue-Sheng Li ,  Huiquan Han

IPC: C07K14/71 ,  C07K14/495 ,  A61K38/00

Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

公开(公告)号：US20170081398A1

公开(公告)日：2017-03-23

申请号：US15367955

申请日：2016-12-02

Applicant: AMGEN INC.

Inventor： Thomas Charles Boone ,  Jonathan Daniel Oliner ,  Eunkyung Lee

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

公开(公告)号：US08920798B2

公开(公告)日：2014-12-30

申请号：US13682580

申请日：2012-11-20

Applicant: Amgen Inc.

Inventor： Huiquan Han ,  Hosung Min ,  Thomas Charles Boone

IPC: A61K39/00 ,  A61K39/395 ,  C12N15/00 ,  C12N15/09 ,  C12N15/13 ,  C12N15/63 ,  C12N5/16 ,  C12N1/21 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/46 ,  G01N33/567 ,  C07K14/475 ,  C07K14/00 ,  A61K38/00

CPC classification number: C07K16/22 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/475 ,  C07K2317/21 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/35 ,  C12N2710/14143 ,  G01N33/567 ,  G01N33/74 ,  G01N2333/475

Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

Abstract translation: 本发明提供了包含能够结合肌生成抑制素并抑制其活性的肽的结合剂。 在一个实施方案中，结合剂包含至少一种与至少一种载体如聚合物或Fc结构域直接或间接连接的肌肉生长抑制素结合肽。 本发明的粘合剂在施用于动物时产生瘦肌肉质量的降低，并且脂肪与肌肉的比例降低。 含有本发明结合剂的治疗组合物可用于治疗肌肉消瘦疾病和代谢紊乱，包括糖尿病和肥胖症。